Exelixis, Inc. (EXEL) bonds
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.50+1.40 (+2.09%)
Close on Nov 17, 2026Market cap $16.71BP/E 20.5Yield –
Debt
Borrowings on the balance sheet, Oct 2, 2026
Exelixis reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2016
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Exelixis's 10-K for the period ended Dec 31, 2021
Exelixis's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed. The repayment schedule above comes from the same report.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size |
|---|---|
| Standby Letters of Credit | $16.70M |
See a number that looks wrong?